Glenmark Pharmaceuticals Ltd has reported a strong financial turnaround in the fourth quarter (Q4) of FY25, posting a net profit of ₹4.7 crore, compared to a loss of ₹1,218 crore in the same period last year. The company’s consolidated revenue for the quarter rose 6.3% YoY to ₹3,256 crore, driven by growth in India and Europe.
Financial Performance and Revenue Growth
For the full fiscal year FY25, Glenmark recorded a 12.8% increase in revenue, reaching ₹13,321.7 crore, while its adjusted profit after tax (PAT) surged to ₹1,389.4 crore. The company’s EBITDA for Q4 stood at ₹561 crore, reflecting an 11.2% YoY growth, with EBITDA margins improving to 17.2%.
Dividend Declaration
The Board of Directors has declared a final dividend of ₹2.5 per equity share, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The total proposed dividend payout stands at ₹70.5 crore, including ₹8.6 crore for retail investors.
Market Expansion and Future Outlook
Glenmark’s India formulation business grew 31.9% YoY, generating ₹4,484.5 crore in revenue, while its Europe segment surged 17.6% to ₹2,846.3 crore. The company remains focused on strengthening its global footprint, with strategic investments in innovation and market expansion.
